Journal profile · PHARMACOLOGY & PHARMACY
Advanced Pharmaceutical Bulletin
ISSN 2228-5881 · eISSN 2251-7308 · Tabriz University of Medical Sciences · Iran, Islamic Republic of
Advanced Pharmaceutical Bulletin: CAS Zone 4 · Medicine (2025 upgraded edition); diamond open access (no APC); no APC; median 185 days to acceptance (101 articles, last 24 months); 97 articles in 2025; indexed in ESCI and Scopus.
Scope
Aims, scope and focus
Advanced Pharmaceutical Bulletin is published by Tabriz University of Medical Sciences and is in Zone 4 of Medicine in the CAS Journal Ranking (2025 upgraded edition). By OpenAlex counts of its recent articles, its largest topics are Advanced Drug Delivery Systems, Advancements in Transdermal Drug Delivery and Nanoparticle-Based Drug Delivery, together about 30.5% of its articles. Its main subfields are Pharmaceutical Science. (generated from OpenAlex topic counts and CAS ranking data)
Advanced Pharmaceutical Bulletin (APB) is a peer-reviewed multidisciplinary open access journal, covering a wide range of integrative fields within Pharmaceutical sciences.
From the journal's Aims & Scope
Research area (LetPub): PHARMACOLOGY & PHARMACY
Main research topics OpenAlex counts of recent articles; shares are approximate
- Advanced Drug Delivery SystemsPharmacology, Toxicology and Pharmaceutics11.6%
- Advancements in Transdermal Drug DeliveryPharmacology, Toxicology and Pharmaceutics10.8%
- Nanoparticle-Based Drug DeliveryMaterials Science8.1%
- Drug Solubulity and Delivery SystemsPharmacology, Toxicology and Pharmaceutics8.1%
- RNA Interference and Gene DeliveryBiochemistry, Genetics and Molecular Biology6.7%
- Mesenchymal stem cell researchMedicine5.5%
- MicroRNA in disease regulationBiochemistry, Genetics and Molecular Biology5.2%
- Electrospun Nanofibers in Biomedical ApplicationsMaterials Science3.5%
Rankings & indexing
CAS ranking and database indexing
CAS Journal Ranking
CAS Journal Ranking, upgraded edition (March 2025)Medicine Zone 4
| Level | Category | Zone |
|---|---|---|
| Major | Medicine | Zone 4 |
| Minor | Pharmacology & Pharmacy | Zone 4 |
Top journal: noReview journal: no
CAS Xinrui Journal Ranking (March 2026)Medicine Zone 3
| Level | Category | Zone |
|---|---|---|
| Major | Medicine | Zone 3 |
| Minor | Pharmacology & Pharmacy | Zone 3 |
Top journal: noReview journal: not marked
CAS Journal Ranking, previous upgraded edition (December 2023)Not covered
Not covered by this edition.
Database indexing
ESCIScopusDOAJLetPub
International journal early-warning lists: not listed in any editionLetPub
Indexing the journal's website claims
PMCPubMedEmbaseCASPublisher website
Other: Google Scholar, EBSCOhost
As the journal's website lists them, not checked against each database; for Web of Science editions the records above apply.
Editions, and major and minor categories, are shown separately and never merged into one zone; check which edition your institution uses before you submit or report.
Metrics
Impact metrics and publication volume
Impact
- CiteScore 2026-06
- 7.7LetPub ·
- SJR 2026-06
- 0.8LetPub ·
- SNIP 2026-06
- 0.88LetPub ·
- h-index
- 67OpenAlex ·
- i10-index
- 510OpenAlex ·
- 2-year mean citedness
- 1.62OpenAlex ·
- Self-citation rate
- 2.1%LetPub ·
- Share of gold OA articles
- 100%LetPub ·
Volume
- Articles per year
- 72LetPub ·
Articles by year OpenAlex count · 1,015 in total · the current year is incomplete
| Year | Articles | Open access | Citations |
|---|---|---|---|
| 2026 | 73 | 73 | 0 |
| 2025 | 97 | 97 | 83 |
| 2024 | 67 | 67 | 302 |
| 2023 | 42 | 42 | 489 |
| 2022 | 55 | 55 | 894 |
| 2021 | 91 | 91 | 1,383 |
Sources count differently and were observed at different times, so each source's own value is kept; "publisher" marks figures from the journal's website.
Review & acceptance
Review time and acceptance
Review time from article dates manuscript dates registered with Crossref · to
185 daysMedian, submission to acceptance · P25–P75 89 days – 256 days
- Acceptance to online
- median 12 days (101 articles)
- Submission to online
- median 197 days
- Sample
- 101 articles with submission and acceptance dates (189 in the window); the latest was accepted on
Only articles that were accepted and published are counted, not the time spent on rejected manuscripts, so this usually runs longer than a publisher's "time to first decision".
Other sources
- Average review time (community reports)
- about 12 weeksLetPub ·
- Submission to publication (journal-reported)
- about 12 weeksDOAJ ·
- Peer review
- Unspecified peer reviewDOAJ
Community reports come from authors' own submissions (confidence 0.5) and are not a promise from the journal; for publisher figures, the journal's own definitions apply.
Fees & open access
APC and open-access policy
Diamond open access (no APC)DOAJ
Every article is open access and authors pay no article processing charge.
| Source | APC | Fee waiver | License | Observed |
|---|---|---|---|---|
| DOAJ | No APC | No | CC BY | |
| LetPub | No APC | No | — | |
| Publisher website | No APC | — | — |
Other charges and waivers (author guidelines)
- Other fees
- No other fees
- Page charges
- No page charges
- Submission fee
- No submission fee
The journal's website is authoritative for fees; sources were observed at different times and each keeps its own value, without averaging.
Submission
Article types and submission policies (journal website)
What to prepare5 items from the author guidelines
- Abstract
- ≤ 250 words
- Manuscript length
- ≤ 8,000 words
- Reference style
- Vancouver
- Suggested reviewers
- Optional
- Cover letter
- Required
Article types accepted8, with length limits
- commentariesCommentaries present the author’s considered opinion (up to ~1000 words limited to one figure/table with four key references) on a scientific or technical subje…Length not stated
- commentaryas follows: A Title, Text, References. Commentaries: Commentaries present the author’s considered opinion (up to ~1000 words limited to one figure/table with fo…main text ≤ 1,000 words
- editorialEditorial: An opinion piece written by the senior editorial staff or publisher.Length not stated
- letterLetter: Comments or concerns on specific subjects; overall or pertaining to items published in the journal. Also, new or additional findings of original nature.Length not stated
- mini reviewcluding tables, figures and references) Mini Review: sharply focused well-focused, well-documented examinations of timely related issues (up to ~4000 words, inc…main text ≤ 4,000 words
- research articleResearch article: Original work resulting from research, constituting complete studies that contain all relevant information. Including systematic review and me…Length not stated
- reviewReview: A full length critical Review.Length not stated
- short communicationShort communication: Original work, but less substantial than the regular research article, presenting preliminary results, or results of immediate relevance.Length not stated
Policy excerpts from the journal's websiteConflicts of interest, Publication ethics, License & copyright, Open access, Peer review, Plagiarism
- Conflicts of interest Competing interests
The authors are required to declare all financial and non-financial competing interests with regards to the publication of their work during submission. Please see our editorial policies for more information on competing interests. If any of the authors are unsure whether they have a competing interest, they should contact the editorial office.
Source ↗Publisher website ·- Publication ethics
Publication ethics and malpractice statement Model summary
Publication ethics, malpractice statement
Source ↗Publisher website ·- License & copyright Open access license, copyright, and charges
Upon submission, the authors are required to sign an exclusive license form for open access publication of their work in the journal under the Creative Commons license 4.0 (CC-BY). The authors retain the copyright to their work. Please see our open access and copyright policy and license agreement for more information. Currently, there are no submission or page or processing charges applicable to …
Source ↗Publisher website ·- Open access Open access license, copyright, and charges
Open access under CC-BY 4.0; authors retain copyright. Model summary
Upon submission, the authors are required to sign an exclusive license form for open access publication of their work in the journal under the Creative Commons license 4.0 (CC-BY). The authors retain the copyright to their work. Please see our open access and copyright policy and license agreement for more information. Currently, there are no submission or page or processing charges applicable to …
Source ↗Publisher website ·- Peer review
Double-blind peer review. Model summary
Since all papers will undergo a double-blind peer review process, the authors are required to upload the "title page" as a separate word file.
Source ↗Publisher website ·- Plagiarism
Plagiarism screening with iThenticate. Model summary
We use iThenticate software in the processing of the submissions.
Source ↗Publisher website ·
Excerpts are quoted from the journal's website; "model summary" lines are written by Workers AI and checked against the text. The journal's website is authoritative.
Profile
Publication details and official links
- Publisher
- Tabriz University of Medical Sciences
- Country or region
- Iran, Islamic Republic of
- Language
- English
- ISSN
- 2228-5881
- Electronic ISSN
- 2251-7308
- Society / sponsor
- Drug Applied Research Center and Faculty of Pharmacy
- Official links
FAQ
Frequently asked questions about Advanced Pharmaceutical Bulletin
What CAS zone is Advanced Pharmaceutical Bulletin in?
In the 2025 upgraded edition of the CAS Journal Ranking, Advanced Pharmaceutical Bulletin is in Zone 4 of Medicine, and in Zone 4 of the minor category Pharmacology & Pharmacy. In the 2026 Xinrui edition it is in Zone 3 of Medicine. Zones from different editions, and from major and minor categories, are not interchangeable.
How long does peer review take at Advanced Pharmaceutical Bulletin?
Based on the dates recorded on 101 articles published between October 2024 and October 2026 (the last 24 months), the median time from submission to acceptance is 185 days (interquartile range 89–256 days); authors report an average review time of about 12 weeks. Article statistics cover accepted papers only, publisher figures follow the journal's own definitions, and community reports come from authors' own submissions; none is a promise from the journal.
What are the manuscript requirements of Advanced Pharmaceutical Bulletin?
According to the journal's author guidelines: Abstract: ≤ 250 words; Manuscript length: ≤ 8,000 words; Reference style: Vancouver; Suggested reviewers: Optional; Cover letter: Required. A model extracted these from the author guidelines and each was checked against the text; check the latest version on the journal's website before submitting.
Which databases index Advanced Pharmaceutical Bulletin?
According to LetPub and DOAJ records, Advanced Pharmaceutical Bulletin is indexed in ESCI, Scopus and DOAJ. The journal's website also lists PMC, PubMed, Embase and CAS; that list has not been checked against each database.
Is Advanced Pharmaceutical Bulletin open access, and what is the APC?
Advanced Pharmaceutical Bulletin is a diamond open-access journal (no APC). It charges no article processing charge.
Sources and updates
The facts on this page come from LetPub, OpenAlex, DOAJ, Publisher website; every figure is tagged with its source and the date it was observed, and conflicting values are kept per source. LetPub source page: view ↗ (archived 2026-08-25). Last updated: .